相关实验视频

Updated: Jul 19, 2026

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

11β-HSD1抑制剂通过通过AMPK/mTOR自途径调节巨细胞极化来缓解败血症引起的心脏功能障碍

Zheng Zhang¹, Binghui Yin², Dongmei Zhu²

¹Department of Emergency Medicine, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, China; Critical Care Center, the First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, 210029, China.

Journal of cardiology

|September 12, 2025

概括

用BVT.2733抑制11β-基固醇脱酶1型 (11β-HSD1) 改善了小鼠在败血症引起的心肌功能障碍. 这种治疗可以通过AMPK/mTOR自途径调节巨分极,从而减少心脏炎症和巨的透.

科学领域:

心血管研究研究心血管研究
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

败血症引起的心肌功能障碍 (SIMD) 是由心脏炎症引起的严重并发症.
11β-基类固醇脱酶1型 (11β-HSD1) 抑制可以减少局部组织炎症.

研究的目的:

调查11β-HSD1抑制剂BVT.2733作为SIMD潜在治疗方法的疗效.

主要方法:

在小鼠中使用脂聚糖 (LPS) 诱导败血症.
评估了BVT.2733对心脏功能障碍,巨细胞透和脏炎症的影响.
在体外研究中使用RAW264.7巨细胞和H9C2心肌细胞来检查BVT.2733的分子机制和对炎症和亡的影响.

主要成果:

在小鼠中,BVT.2733的使用改善了LPS诱导的心脏功能障碍,M1巨细胞透和心脏炎症.
抑制剂减少了脏损伤和炎症,抑制了M1巨分化在体外,并降低了心肌细胞亡.
机制研究表明BVT.2733激活AMPK/mTOR信号通路,增加自.

结论:

11β-HSD1抑制剂BVT.2733在治疗小鼠SIMD和LPS诱导的心肌损伤方面显示出有前途.
治疗效益与通过AMPK/mTOR介导的自途径调节巨分化有关.

关键词:

11β-基类固醇脱酶1型在BVT.273333中使用.炎症炎症是一种炎症.巨细胞是一个巨细胞.败血症引起的心肌功能障碍

更多相关视频

Cecal Ligation and Puncture-induced Sepsis as a Model To Study Autophagy in Mice

Cecal Ligation and Puncture-induced Sepsis as a Model To Study Autophagy in Mice

Published on: February 9, 2014

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

相关概念视频

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...